KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Travere Therapeutics (TVTX) over the last 16 years, with Q3 2025 value amounting to $14.2 million.

  • Travere Therapeutics' Free Cash Flow rose 13335.22% to $14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.8 million, marking a year-over-year increase of 7793.15%. This contributed to the annual value of -$237.5 million for FY2024, which is 2716.05% up from last year.
  • Travere Therapeutics' Free Cash Flow amounted to $14.2 million in Q3 2025, which was up 13335.22% from $5.0 million recorded in Q2 2025.
  • Travere Therapeutics' 5-year Free Cash Flow high stood at $31.7 million for Q3 2021, and its period low was -$119.0 million during Q1 2024.
  • Over the past 5 years, Travere Therapeutics' median Free Cash Flow value was -$42.5 million (recorded in 2024), while the average stood at -$48.9 million.
  • Per our database at Business Quant, Travere Therapeutics' Free Cash Flow surged by 63293.27% in 2021 and then plummeted by 67598.94% in 2022.
  • Over the past 5 years, Travere Therapeutics' Free Cash Flow (Quarter) stood at -$88.5 million in 2021, then increased by 13.27% to -$76.7 million in 2022, then rose by 16.08% to -$64.4 million in 2023, then surged by 44.53% to -$35.7 million in 2024, then soared by 139.69% to $14.2 million in 2025.
  • Its last three reported values are $14.2 million in Q3 2025, $5.0 million for Q2 2025, and -$42.2 million during Q1 2025.